EIDD-2801 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。EIDD-2801 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性,如 SARS-CoV-2,MERS-CoV,SARS-CoV。EIDD-2801 有用于 COVID-19 和季节性,流行性流感的潜力。
EIDD-2801可抑制多种RNA病毒的复制,包括SARS-CoV-2(COVID-19的致病因子),通过两种不同冠状病毒(SARS-CoV1和MERS)的动物研究,证明EIDD-2801可以改善肺功能、减少体重减轻并减少肺中的病毒量。除了针对冠状病毒的活性外,在实验室研究中,EIDD-2801还显示出针对季节性流感、呼吸道合胞病毒、基孔肯雅病毒、埃博拉病毒、委内瑞拉马脑炎病毒和东部马脑炎病毒的活性。
Molnupiravir ;EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. EIDD-2801 is a prodrug of EIDD-1931.
浙江华纳药业有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!